Amgen Inc. (NASDAQ:AMGN) has been given a consensus recommendation of “Buy” by the twenty-two research firms that are currently covering the firm. One research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation, eleven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $183.58.
Several equities research analysts have issued reports on the company. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a report on Saturday, September 17th. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $171.34 price target for the company in a report on Wednesday, August 3rd. Credit Suisse Group AG set a $206.00 price target on Amgen and gave the company a “buy” rating in a report on Saturday, September 17th. Robert W. Baird reaffirmed an “outperform” rating and set a $157.00 price target on shares of Amgen in a report on Friday, August 26th. Finally, Citigroup Inc. raised their price target on Amgen from $165.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, July 29th.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.20% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the stock. Integrated Wealth Management raised its position in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock valued at $141,000 after buying an additional 3 shares during the period. Goelzer Investment Management Inc. raised its position in shares of Amgen by 0.3% in the second quarter. Goelzer Investment Management Inc. now owns 1,604 shares of the medical research company’s stock valued at $244,000 after buying an additional 5 shares during the period. Nadler Financial Group Inc. raised its position in shares of Amgen by 0.3% in the second quarter. Nadler Financial Group Inc. now owns 2,111 shares of the medical research company’s stock valued at $321,000 after buying an additional 6 shares during the period. Capital Advisors Ltd. LLC raised its position in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock valued at $164,000 after buying an additional 6 shares during the period. Finally, Parkside Financial Bank & Trust raised its position in shares of Amgen by 0.4% in the second quarter. Parkside Financial Bank & Trust now owns 1,463 shares of the medical research company’s stock valued at $223,000 after buying an additional 6 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amgen (NASDAQ:AMGN) opened at 166.81 on Friday. Amgen has a 52 week low of $138.06 and a 52 week high of $176.85. The firm has a market cap of $124.83 billion, a P/E ratio of 17.07 and a beta of 0.87. The stock has a 50 day moving average of $171.68 and a 200 day moving average of $161.02.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. During the same quarter last year, the firm posted $2.57 EPS. The company’s quarterly revenue was up 5.9% on a year-over-year basis. Analysts anticipate that Amgen will post $11.36 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were paid a $1.00 dividend. This represents a $4.00 annualized dividend and a yield of 2.40%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 40.90%.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.